

205844120

Company registration number: BR023687


**Dem Pharmaceuticals UK**

**Unaudited filleted financial statements**

**for the period ended**

**31 May 2022**

SATURDAY



\*ABW6UN5M\*

A14

28/01/2023

#8

COMPANIES HOUSE

## **Dem Pharmaceuticals UK**

### **Contents**

	<b>Page</b>
Directors and other information	<b>1</b>
Statement of financial position	<b>2 - 3</b>
Notes to the financial statements	<b>4 - 5</b>

**Dem Pharmaceuticals UK**

**Directors and other information**

<b>Directors</b>	Yeliz Demir Deniz Demir Aydin Demir
<b>Company number</b>	BR023687
<b>Registered office</b>	First Floor 140 Brompton Road London SW3 1HY
<b>Accountants</b>	Redford & Co Limited Chartered Accountants 64 Baker Street London W1U 7GB

**Dem Pharmaceuticals UK**

**Statement of financial position  
31 May 2022**

	Note	31/05/22 £	£
<b>Current assets</b>			
Cash at bank and in hand		21,320	
		<u>21,320</u>	
<b>Creditors: amounts falling due within one year</b>	5	(143,936)	
<b>Net current liabilities</b>			(122,616)
<b>Total assets less current liabilities</b>			(122,616)
<b>Net liabilities</b>			<u>(122,616)</u>
<b>Capital and reserves</b>			
Profit and loss account			(122,616)
<b>Shareholders deficit</b>			<u>(122,616)</u>

For the period ending 31 May 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

**Directors responsibilities:**

- The members have not required the company to obtain an audit of its financial statements for the period in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.

**The notes on pages 4 to 5 form part of these financial statements.**

**Dem Pharmaceuticals UK**

**Statement of financial position (continued)**  
**31 May 2022**

These financial statements were approved by the board of directors and authorised for issue on 9 December 2022, and are signed on behalf of the board by:



Yeliz Demir  
Director

Company registration number: BR023687

**The notes on pages 4 to 5 form part of these financial statements.**

## **Dem Pharmaceuticals UK**

### **Notes to the financial statements Period ended 31 May 2022**

#### **1. General information**

The company is a private company limited by shares, and established in Turkey. The address of the UK office is First Floor 140 Brompton Road, London, SW3 1HY.

#### **2. Statement of compliance**

These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

#### **3. Accounting policies**

##### **Basis of preparation**

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

##### **Taxation**

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

##### **Financial instruments**

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

**Dem Pharmaceuticals UK**

**Notes to the financial statements (continued)**  
**Period ended 31 May 2022**

**4. Staff costs**

The average number of persons employed by the company during the period amounted to 3.

The aggregate payroll costs incurred during the period were:

	<b>Period ended 31/05/22 £</b>
Wages and salaries	105,346
Social security costs	12,430
	<u>117,776</u>

**5. Creditors: amounts falling due within one year**

	<b>31/05/22 £</b>
Trade creditors	312
Amounts owed to group undertakings and undertakings in which the company has a participating interest	121,471
Social security and other taxes	3,275
Other creditors	18,878
	<u>143,936</u>